花蓮慈濟醫院公傳室 06-泌尿科點擊數: 235

張嘉峰科主任

網路掛號

專長

一般泌尿學
尿路結石治療
攝護腺肥大
排尿障礙
一般泌尿科手術
生殖泌尿道感染
男性不孕症

佛教慈濟醫療財團法人花蓮慈濟醫院泌尿部內視鏡泌尿科主任
慈濟大學部定講師
台灣泌尿科醫學會 -- 功能性泌尿學委員會
台灣泌尿科醫學會 -- 資訊及線上教育委員會委員
台灣泌尿科醫學會 -- 專科醫師甄審委員會委員

【2013】

Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. Jhang JF, Jiang YH, Kuo HC. Int J Clin Pract. 2013 Dec;67(12):1327-33 (SCI)
Transurethral Incision of the bladder neck improves voiding efficiency in female patients with detrusor underactivity. Jhang JF, Jiang YH, Kuo HC. Int Urogynecol J. 2014 May;25(5):671-6. (SCI)
Down Regulation of Vascular Endothelial Growth Factor Is Associated With Decreased Inflammation After Intravesical OnabotulinumtoxinA Injections Combined With Hydrodistention for Patients With Interstitial Cystitis-Clinical Results and Immunohistochemistry Analysis. Peng CH, Jhang JF, Shie JH, Kuo HC. Urology. 2013 Dec ;82(6):1452.e1-6. (SCI)
Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia. Jia-Fong Jhang, Chun-Hou Liao, Hann-Chorng Kuo. Int J Clin Pract. 2014 Jun;68(6):743-8. (SCI)
Characteristics and electrocauterization of Hunner's lesions associated with bladder pain syndrome Urological Science, Volume 24, Issue 2, June 2013, Pages 51-55. Jia-Fong Jhang, Yung-Hsiang Hsu, Hann-Chorng Kuo
【2014】
Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Jia-Fong Jhang, Hann-Chorng Kuo. Int J Urol 2014 Apr;21 Suppl 1:49-55 (SCI)
Elevated Serum Immunoglobulin E May Be Associated to the Development of Ketamine Cystitis. Jhang JF, Hsu YH, Jiang YH, Kuo HC. J Urol. 2014 Oct;192(4):1249-56 (SCI)
【2015】
Possible Pathophysiology of Ketamine-Related Cystitis and associated Treatment Srategies. Jhang JF, Hsu YH, Kuo HC. Int J Urol. 2015 Sep;22(9):816-25. (SCI)
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection. Jhang JF, Kuo HC. Toxins (Basel). 2015 Jun 18;7(6):2232-50 (SCI)
Role of serum immunoglobulin E in patients with interstitial cystitis/bladder pain syndrome. Jhang JF, Kuo HC. Urological Science 26 (2015) 202-205
Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. Jhang JF, Jiang YH, Lee CL, Kuo HC. J Formos Med Assoc. 2015 Sep 12. pii: S0929-6646(15)00307-1 (SCI)
【2016】
The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis – an Immunohistochemical Study. Jhang JF, Hsu YH, Jiang YH, Kuo HC. Pain physician 2016 19(4):E581-7.
Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Jhang JF, Birder LA, Chancellor MB, Kuo HC. Neurourol Urodyn. 2016 Mar 21. (SCI)
Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis. Jiang YH, Jhang JF, Kuo HC. PLoS One. 2016 Mar 21;11(3):e0151692. (SCI)
Urothelial functional protein and sensory receptors in patients with interstitial cystitis/bladder pain syndrome with and without Hunner’s lesion. Jhang JF, Hsu YH, Kuo HC. Urology 2016 Dec;98:44-49 (SCI)
【2017】
Bladder dysfunction in 2016: New insights into interstitial cystitis and chronic pelvic pain syndromes. Jhang JF, Kuo HC. Nat Rev Urol. 2017 Feb;14(2):69-70. (SCI)
Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease. Jhang JF, Kuo HC. Int Neurourol J. 2016 Nov;20(Suppl 2):S95-104. Epub 2016 Nov 22 (SCI)
Clinical Outcome of Augmentation Enterocystoplasty for Patients with Ketamine-induced Cystitis. Lee YK, Jhang JF, Kuo HC. Pain Physician. 2017 Mar;20(3):E431-E436.(SCI)
Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. Jhang JF, Kuo HC.Ci Ji Yi Xue Za Zhi. 2017 Jul-Sep;29(3):131-137.Review (SCI)
Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Jiang YH, Jhang JF, Chen SF, Kuo HC.Low Urin Tract Symptoms. 2017 Oct 11. doi: 10.1111/luts.12195. [Epub ahead of print] (SCI)
Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. Jhang JF, Wu SY, Lin TY, Kuo HC.Low Urin Tract Symptoms. 2017 Dec 19. doi: 10.1111/luts.12212. [Epub ahead of print] (SCI)
Current pharmacological and surgical treatment of underactive bladder. Jiang YH, Lee CL, Jhang JF, Kuo HC.Ci Ji Yi Xue Za Zhi. 2017 Oct-Dec;29(4):187-191. doi: 10.4103/tcmj.tcmj_122_17. Review. (SCI)
【2018】
Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. Jiang YH, Jhang JF, Lee CL, Kuo HC.Neurourol Urodyn. 2018 Apr;37(4):1467-1473. doi: 10.1002/nau.23475. (SCI)
Histopathological characteristics of ketamine-associated uropathy and their clinical association. Jhang JF, Hsu YH, Jiang YH, Lee CL, Kuo HC. Neurourol Urodyn. 2018 Feb 14. doi: 10.1002/nau.23514. [Epub ahead of print] (SCI)
Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy. Chen YC, Jhang JF, Hsu YH, Kuo HC. Low Urin Tract Symptoms. 2018 Mar 11. doi: 10.1111/luts.12221. [Epub ahead of prin] (SCI)
Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC. J Urol. 2018 Apr 11. pii: S0022-5347(18)42926-6. doi: 10.1016/j.juro.2018.03.133. [Epub ahead of print] (SCI)
Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Jiang YH, Chen SF, Jhang JF, Kuo HC. Neurourol Urodyn. 2018 May 24. doi: 10.1002/nau.23714. [Epub ahead of print] (SCI)
Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. PLoS One. 2018 Jun 7;13(6):e0198816. doi: 10.1371/journal.pone.0198816. eCollection 2018.(SCI)
Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. Jhang JF, Kuo HC. Toxins (Basel). 2018 Jun 26;10(7). pii: E260. doi: 10.3390/toxins10070260. Review. (SCI)
Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. Jiang YH, Jhang JF, Lee CL, Kuo HC.Neurourol Urodyn. 2018 Apr;37(4):1467-1473. doi: 10.1002/nau.23475. (SCI)
Histopathological characteristics of ketamine-associated uropathy and their clinical association. Jhang JF, Hsu YH, Jiang YH, Lee CL, Kuo HC. Neurourol Urodyn. 2018 Feb 14. doi: 10.1002/nau.23514. [Epub ahead of print] (SCI)
Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy. Chen YC, Jhang JF, Hsu YH, Kuo HC. Low Urin Tract Symptoms. 2018 Mar 11. doi: 10.1111/luts.12221. [Epub ahead of prin] (SCI)
Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC. J Urol. 2018 Apr 11. pii: S0022-5347(18)42926-6. doi: 10.1016/j.juro.2018.03.133. [Epub ahead of print] (SCI)
Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Jiang YH, Chen SF, Jhang JF, Kuo HC. Neurourol Urodyn. 2018 May 24. doi: 10.1002/nau.23714. [Epub ahead of print] (SCI)
Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. PLoS One. 2018 Jun 7;13(6):e0198816. doi: 10.1371/journal.pone.0198816. eCollection 2018.(SCI)
Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. Jhang JF, Kuo HC. Toxins (Basel). 2018 Jun 26;10(7). pii: E260. doi: 10.3390/toxins10070260. Review. (SCI)
Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome.Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC.J Urol. 2018 Sep;200(3):590-596. doi: 10.1016/j.juro.2018.03.133. Epub 2018 Apr 11.PMID: 29653163
Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity.Jiang YH, Chen SF, Jhang JF, Kuo HC.Neurourol Urodyn. 2018 Nov;37(8):2651-2657. doi: 10.1002/nau.23714. Epub 2018 May 24.PMID: 29797345
【2019】
Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity.Jiang YH, Jhang JF, Chen SF, Kuo HC.Low Urin Tract Symptoms. 2019 Jan;11(1):66-71. doi: 10.1111/luts.12195. Epub 2017 Oct 11.PMID: 29024564
Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial.Jhang JF, Lin TY, Kuo HC.Neurourol Urodyn. 2019 Feb;38(2):703-709. doi: 10.1002/nau.23898. Epub 2018 Dec 21.PMID: 30576011
Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study.Jhang JF, Wu SY, Lin TY, Kuo HC.Low Urin Tract Symptoms. 2019 Apr;11(2):O42-O47. doi: 10.1111/luts.12212. Epub 2017 Dec 19.PMID: 29265766
Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy.Chen YC, Jhang JF, Hsu YH, Kuo HC.Low Urin Tract Symptoms. 2019 Apr;11(2):O221-O223. doi: 10.1111/luts.12221. Epub 2018 Mar 11.PMID: 29527818
Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency.Ke QS, Jhang JF, Lin TY, Ho HC, Jiang YH, Hsu YH, Kuo HC.Ci Ji Yi Xue Za Zhi. 2019 Jul-Sep;31(3):135-143. doi: 10.4103/tcmj.tcmj_92_19.PMID: 31258287 Free PMC article. Review.
Long-term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow-up and treatment.Yeh HL, Jhang JF, Kuo YC, Kuo HC.Neurourol Urodyn. 2019 Sep;38(7):1985-1993. doi: 10.1002/nau.24104. Epub 2019 Jul 16.PMID: 31310370
Upregulation of neurotrophins and transforming growth factor-β expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitis.Jhang JF, Wang HJ, Hsu YH, Birder LA, Kuo HC.Neurourol Urodyn. 2019 Nov;38(8):2303-2310. doi: 10.1002/nau.24139. Epub 2019 Aug 21.PMID: 31433072
Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Possible Pathomechanisms and Practical Issues.Jhang JF.Toxins (Basel). 2019 Nov 4;11(11):641. doi: 10.3390/toxins11110641.PMID: 31689912 Free PMC article. Review.
Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome.Jhang JF, Birder LA, Jiang YH, Hsu YH, Ho HC, Kuo HC.Sci Rep. 2019 Dec 16;9(1):19169. doi: 10.1038/s41598-019-55584-y.PMID: 31844086 Free PMC article.
【2020】
Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics.Jiang YH, Jhang JF, Hsu YH, Ho HC, Wu YH, Kuo HC.Am J Physiol Renal Physiol. 2020 Jun 1;318(6):F1391-F1399. doi: 10.1152/ajprenal.00051.2020. Epub 2020 Apr 13.PMID: 32281420 Free article.
Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis.Jiang YH, Kuo YC, Jhang JF, Lee CL, Hsu YH, Ho HC, Kuo HC.Sci Rep. 2020 Sep 16;10(1):15218. doi: 10.1038/s41598-020-72292-0.PMID: 32939046 Free PMC article. Clinical Trial.
【2021】
Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification.Jhang JF, Hsu YH, Jiang YH, Ho HC, Kuo HC.J Urol. 2021 Jan;205(1):226-235. doi: 10.1097/JU.0000000000001334. Epub 2020 Aug 28.PMID: 32856961
Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment.Yu WR, Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC.Sci Rep. 2021 Jan 11;11(1):455. doi: 10.1038/s41598-020-80252-x.PMID: 33432045 Free PMC article.
Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm.Jiang YH, Jhang JF, Hsu YH, Ho HC, Wu YH, Kuo HC.Sci Rep. 2021 Jan 13;11(1):914. doi: 10.1038/s41598-020-80131-5.PMID: 33441752 Free PMC article.
Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4.Yang HH, Jhang JF, Hsu YH, Jiang YH, Zhai WJ, Kuo HC.Sci Rep. 2021 Mar 4;11(1):5200. doi: 10.1038/s41598-021-84734-4.PMID: 33664402 Free PMC article.
Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions in patients with recurrent and persistent urinary tract infections.Jhang JF, Lin TY, Ho HC, Jiang YH, Hsu YH, Birder LA, Kuo HC.Low Urin Tract Symptoms. 2021 Apr;13(2):203-209. doi: 10.1111/luts.12351. Epub 2020 Nov 1.PMID: 33135375
Urothelial health after platelet-rich plasma injection in intractable recurrent urinary tract infection: Improved cell proliferation, cytoskeleton, and barrier function protein expression.Jiang YH, Jhang JF, Hsu YH, Ho HC, Lin TY, Birder LA, Kuo HC.Low Urin Tract Symptoms. 2021 Apr;13(2):271-278. doi: 10.1111/luts.12364. Epub 2020 Nov 16.PMID: 33197967
Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders.Jhang JF, Kuo HC.Toxins (Basel). 2021 May 18;13(5):359. doi: 10.3390/toxins13050359.PMID: 34069951 Free PMC article. Review.
Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation might be different from other types of patients.Jhang JF, Jiang YH, Hsu YH, Ho HC, Kuo HC.Int J Urol. 2021 Aug;28(8):823-830. doi: 10.1111/iju.14585. Epub 2021 May 8.PMID: 33966299
Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics.Lee YK, Jhang JF, Jiang YH, Hsu YH, Ho HC, Kuo HC.Sci Rep. 2021 Aug 26;11(1):17258. doi: 10.1038/s41598-021-96810-w.PMID: 34446784 Free PMC article.
Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome.Jhang JF, Hsu YH, Ho HC, Jiang YH, Lee CL, Yu WR, Kuo HC.Biomedicines. 2021 Sep 24;9(10):1306. doi: 10.3390/biomedicines9101306.PMID: 34680422 Free PMC article.
Ultrastructural changes in the underactive bladder.Ho HC, Hsu YH, Jhang JF, Jiang YH, Kuo HC.Tzu Chi Med J. 2020 Sep 16;33(4):345-349. doi: 10.4103/tcmj.tcmj_153_20. eCollection 2021 Oct-Dec.PMID: 34760629 Free PMC article. Review.
【2022】
Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction.Lee CL, Jhang JF, Jiang YH, Kuo HC.Toxins (Basel). 2022 Jan 2;14(1):30. doi: 10.3390/toxins14010030.PMID: 35051007 Free PMC article.
Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury.Chen SF, Jiang YH, Jhang JF, Kuo HC.Toxins (Basel). 2022 Jan 3;14(1):35. doi: 10.3390/toxins14010035.PMID: 35051012 Free PMC article.
Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification.Lee CL, Jhang JF, Ho HC, Jiang YH, Hsu YH, Kuo HC.Sci Rep. 2022 Jan 10;12(1):362. doi: 10.1038/s41598-021-04237-0.PMID: 35013465 Free PMC article.
Inflammation and Barrier Function Deficits in the Bladder Urothelium of Patients with Chronic Spinal Cord Injury and Recurrent Urinary Tract Infections.Wu SY, Jiang YH, Jhang JF, Hsu YH, Ho HC, Kuo HC.Biomedicines. 2022 Jan 20;10(2):220. doi: 10.3390/biomedicines10020220.PMID: 35203430 Free PMC article.
Bladder Ultrastructure and Urinary Cytokine Abnormality in Patients with Recurrent Urinary Tract Infection and the Changes after Intravesical Platelet-Rich Plasma Injections.Jhang JF, Ho HC, Hsu YH, Jiang YH, Kuo HC.Biomedicines. 2022 Jan 24;10(2):245. doi: 10.3390/biomedicines10020245.PMID: 35203455 Free PMC article.
Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection.Jhang JF, Jiang YH, Hsu YH, Ho HC, Birder LA, Lin TY, Kuo HC.Int Neurourol J. 2022 Feb;26(Suppl 1):S57-67. doi: 10.5213/inj.2142100.050. Epub 2022 Jan 20.PMID: 35073671 Free PMC article.
Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment.Jiang YH, Jhang JF, Lee YK, Kuo HC.Biomedicines. 2022 Feb 7;10(2):396. doi: 10.3390/biomedicines10020396.PMID: 35203604 Free PMC article. Review.
Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome-A Comparative Study of Different Injection Number, Additives and Concentrations.Jiang YH, Jhang JF, Lin TY, Ho HC, Hsu YH, Kuo HC.Front Pharmacol. 2022 Mar 22;13:853776. doi: 10.3389/fphar.2022.853776. eCollection 2022.PMID: 35392571 Free PMC article.
Diagnostic and prognostic value of urine biomarkers among women with dysfunctional voiding.Jiang YH, Jhang JF, Ho HC, Hsu YH, Kuo HC.Sci Rep. 2022 Apr 22;12(1):6608. doi: 10.1038/s41598-022-10696-w.PMID: 35459903 Free PMC article.
Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?Jiang YH, Jhang JF, Kuo HC.Diagnostics (Basel). 2022 Apr 27;12(5):1093. doi: 10.3390/diagnostics12051093.PMID: 35626252 Free PMC article.
Clinical Correlation of Bladder Electron Microscopic Characteristics in Patients with Detrusor Underactivity of Various Etiologies.Jhang JF, Ho HC, Jiang YH, Hsu YH, Kuo HC.Biomedicines. 2022 May 3;10(5):1055. doi: 10.3390/biomedicines10051055.PMID: 35625793 Free PMC article.
Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome.Yu WR, Jiang YH, Jhang JF, Kuo HC.Biomedicines. 2022 May 17;10(5):1149. doi: 10.3390/biomedicines10051149.PMID: 35625885 Free PMC article.
Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma.Lee YK, Jiang YH, Jhang JF, Ho HC, Kuo HC.Biomedicines. 2022 May 20;10(5):1182. doi: 10.3390/biomedicines10051182.PMID: 35625918 Free PMC article.
Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics.Chen SF, Jhang JF, Jiang YH, Kuo HC.Int Urol Nephrol. 2022 Jun;54(6):1215-1223. doi: 10.1007/s11255-022-03175-8. Epub 2022 Mar 16.PMID: 35294677
Corrigendum: Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection.Jhang JF, Jiang YH, Hsu YH, Ho HC, Birder LA, Lin TY, Kuo HC.Int Neurourol J. 2022 Jun;26(2):169. doi: 10.5213/inj.2221050.corrigendum. Epub 2022 Jun 30.PMID: 35793995 Free PMC article. No abstract available.
Pathogenesis evidence from human and animal models of detrusor underactivity.Jhang JF, Jiang YH, Hsu YH, Ho HC, Kuo HC.Tzu Chi Med J. 2021 May 11;34(3):287-296. doi: 10.4103/tcmj.tcmj_284_20. eCollection 2022 Jul-Sep.PMID: 35912048 Free PMC article. Review.
Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome.Jiang YH, Jhang JF, Ho HC, Chiou DY, Kuo HC.Biomedicines. 2022 Jul 14;10(7):1701. doi: 10.3390/biomedicines10071701.PMID: 35885006 Free PMC article.
Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome.Jhang JF, Jiang YH, Kuo HC.Biomedicines. 2022 Sep 23;10(10):2380. doi: 10.3390/biomedicines10102380.PMID: 36289642 Free PMC article. Review.
Potential urine biomarkers in bladder outlet obstruction-related detrusor underactivity.Jiang YH, Jhang JF, Hsu YH, Ho HC, Kuo HC.Tzu Chi Med J. 2021 Apr 5;34(4):388-393. doi: 10.4103/tcmj.tcmj_298_20. eCollection 2022 Oct-Dec.PMID: 36578642 Free PMC article. Review.
Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.Jiang YH, Jhang JF, Hsu YH, Kuo HC.Int J Mol Sci. 2022 Oct 10;23(19):12044. doi: 10.3390/ijms231912044.PMID: 36233356 Free PMC article.
Multimodal Treatment with Cognitive Behavioral Therapeutic Intervention Plus Bladder Treatment Is More Effective than Monotherapy for Patients with Interstitial Cystitis/Bladder Pain Syndrome-A Randomized Clinical Trial.Yu WR, Jhang JF, Chen BY, Ou SR, Li HM, Kuo HC.J Clin Med. 2022 Oct 21;11(20):6221. doi: 10.3390/jcm11206221.PMID: 36294541 Free PMC article.
Long-Term Surveillance and Management of Urological Complications in Chronic Spinal Cord-Injured Patients.Wu SY, Jhang JF, Liu HH, Chen JT, Li JR, Chiu B, Chen SL, Kuo HC.J Clin Med. 2022 Dec 9;11(24):7307. doi: 10.3390/jcm11247307.PMID: 36555924 Free PMC article. Review.
Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome.Yu WR, Jiang YH, Jhang JF, Chang WC, Kuo HC.Toxins (Basel). 2022 Dec 11;14(12):871. doi: 10.3390/toxins14120871.PMID: 36548768 Free PMC article.
The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis.Jiang YH, Jhang JF, Kuo HC.Tzu Chi Med J. 2022 Mar 11;35(1):31-37. doi: 10.4103/tcmj.tcmj_313_21. eCollection 2023 Jan-Mar.PMID: 36866354 Free PMC article. Review.
【2023】
Sensory Receptor, Inflammatory, and Apoptotic Protein Expression in the Bladder Urothelium of Patients with Different Subtypes of Interstitial Cystitis/Bladder Pain Syndrome.Jiang YH, Jhang JF, Birder LA, Kuo HC.Int J Mol Sci. 2023 Jan 3;24(1):820. doi: 10.3390/ijms24010820.PMID: 36614264 Free PMC article.
Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment.Jhang JF, Yu WR, Kuo HC.Toxins (Basel). 2023 Feb 2;15(2):121. doi: 10.3390/toxins15020121.PMID: 36828435 Free PMC article.
Discriminating Different Bladder and Bladder Outlet Dysfunctions by Urinary Biomarkers in Women with Frequency-Urgency Syndrome.Jhang JF, Jiang YH, Kuo HC.Biomedicines. 2023 Feb 23;11(3):673. doi: 10.3390/biomedicines11030673.PMID: 36979652 Free PMC article.
EBV infection mediated BDNF expression is associated with bladder inflammation in interstitial cystitis/bladder pain syndrome with Hunner's lesion.Jhang JF, Liu CD, Hsu YH, Chen CC, Chen HC, Jiang YH, Wu WC, Peng CW, Kuo HC.J Pathol. 2023 Mar;259(3):276-290. doi: 10.1002/path.6040. Epub 2022 Dec 23.PMID: 36441149
Urinary Oxidative Stress Biomarker Levels Might Be Useful in Identifying Functional Bladder Disorders in Women with Frequency and Urgency Syndrome.Jiang YH, Jhang JF, Kuo HC.J Clin Med. 2023 Mar 17;12(6):2336. doi: 10.3390/jcm12062336.PMID: 36983336 Free PMC article.
Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients.Jiang YH, Jhang JF, Wu YH, Kuo HC.Biomedicines. 2023 Apr 17;11(4):1191. doi: 10.3390/biomedicines11041191.PMID: 37189809 Free PMC article.
Pathophysiology, clinical presentation, and management of ketamine-induced cystitis.Jhang JF, Birder LA, Kuo HC.Tzu Chi Med J. 2023 Jun 13;35(3):205-212. doi: 10.4103/tcmj.tcmj_94_23. eCollection 2023 Jul-Sep.PMID: 37545795 Free PMC article.
Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions.Yu WR, Jiang YH, Jhang JF, Kuo HC.Int J Mol Sci. 2023 Jul 27;24(15):12055. doi: 10.3390/ijms241512055.PMID: 37569430 Free PMC article.
The Tumor Necrosis Factor-α Level in Platelet-Rich Plasma Might Be Associated with Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome or Recurrent Urinary Tract Infection.Jhang JF, Jiang YH, Lin TY, Kuo HC.Int J Mol Sci. 2023 Dec 21;25(1):163. doi: 10.3390/ijms25010163.PMID: 38203334 Free PMC article.
Cystoscopic characteristic findings of interstitial cystitis and clinical implications.Yu WR, Jiang YH, Jhang JF, Kuo HC.Tzu Chi Med J. 2023 Aug 22;36(1):30-37. doi: 10.4103/tcmj.tcmj_172_23. eCollection 2024 Jan-Mar.PMID: 38406570 Free PMC article. Review.
【2024】
Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome.Yu WR, Jhang JF, Kuo HC.Toxins (Basel). 2024 Feb 1;16(2):74. doi: 10.3390/toxins16020074.PMID: 38393152 Free PMC article.
Hypermethylation Loci of ZNF671, IRF8, and OTX1 as Potential Urine-Based Predictive Biomarkers for Bladder Cancer.Jiang YH, Liu YS, Wei YC, Jhang JF, Kuo HC, Huang HH, Chan MWY, Lin GL, Cheng WC, Lin SC, Wang HJ.Diagnostics (Basel). 2024 Feb 21;14(5):468. doi: 10.3390/diagnostics14050468.PMID: 38472940 Free PMC article.
Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions.Jiang YH, Jhang JF, Chen SF, Kuo HC.Toxins (Basel). 2024 Mar 1;16(3):123. doi: 10.3390/toxins16030123.PMID: 38535789
Combination of urinary biomarkers and machine-learning models provided a higher predictive accuracy to predict long-term treatment outcomes of patients with interstitial cystitis/bladder pain syndrome.Jhang JF, Yu WR, Huang WT, Kuo HC.World J Urol. 2024 Mar 20;42(1):173. doi: 10.1007/s00345-024-04843-3.PMID: 38507059

00-醫師

張嘉峰 科主任

專長

花蓮慈濟醫院《守護生命 守護健康 守護愛》

張嘉峰科主任

花蓮慈濟醫院《守護生命守護健康守護愛》